Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-inflammatory antibody ALXN1007

A proprietary antibody that targets the complement inflammatory pathway with potential immunomodulating and anti-inflammatory activities. Upon intravenous administration, anti-inflammatory antibody ALXN1007 modulates the complement inflammatory pathway through binding to an as of yet undisclosed target. This may help in the treatment of certain inflammatory-mediated disorders, such as antiphospholipid syndrome (APS). This agent may also influence the progression of graft-versus-host disease (GvHD).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:ALXN 1007
ALXN-1007
ALXN1007
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search